Ovulation Inhibition With A New Vaginal Ring Containing Trimegestone

摘要

Women receiving combined hormonal contraceptives (CHCs) are at increased risk of stroke, myocardial infarction, or venous thromboembolism, whereas those receiving progestogen-only preparations for contraception have little or no increased risk of these complications. However, the progestogen-only pills (POPs) currently marketed in the United States all have drawbacks. These include lower contraceptive efficacy of traditional POPs containing norethindrone or (levo)norgestrel than that of CHCs, due to incomplete inhibition of ovulation, and the unpredictable bleeding pattern of all POPS, because of the continuous intake regimen.